Ratings by Goldman Sachs (Corinne Johnson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/2/2026 | Neurocrine Bio. | NBIX | New Coverage | Buy (N/A) |
161.00 (156.76) |
-2.63% | Details | |
| 5/15/2026 | ORIC Pharmaceuticals | ORIC | Upgrade | Buy (Early-Stage Biotech) |
8.34 (12.89) |
54.56% | Details | |
| 5/15/2026 | Prelude Therapeutics | PRLD | New Coverage | Early-Stage Biotech (N/A) |
4.47 (5.49) |
22.82% | Details | |
| 4/24/2026 | Altimmune | ALT | Upgrade | Neutral (Sell) |
2.89 (3.09) |
6.92% | Details | |
| 4/15/2026 | Immunovant | IMVT | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2026 | Biohaven Pharma | BHVN | New Coverage | Buy (N/A) |
10.99 (15.74) |
43.22% | Details | |
| 12/4/2025 | Tyra Biosciences | TYRA | New Coverage | Early-Stage Biotech (N/A) |
21.70 (25.30) |
16.59% | Details | |
| 12/4/2025 | MBX Biosciences Inc | MBX | New Coverage | Sell (N/A) |
33.94 (60.93) |
79.52% | Details | |
| 12/4/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Early-Stage Biotech (N/A) |
10.98 (8.34) |
-24.04% | Details | |
| 11/4/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 8/27/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Nurix | NRIX | New Coverage | Buy (N/A) |
13.18 (26.04) |
97.57% | Details | |
| 7/10/2025 | Immunovant | IMVT | New Coverage | Neutral (N/A) |
17.29 (39.90) |
130.77% | Details | |
| 7/10/2025 | CG Oncology | CGON | New Coverage | Buy (N/A) |
27.04 (75.86) |
180.55% | Details | |
| 7/10/2025 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
21.34 (30.15) |
41.28% | Details | |
| 7/10/2025 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
31.27 (13.77) |
-55.96% | Details | |
| 7/10/2025 | Neurocrine Bio. | NBIX | New Coverage | Buy (N/A) |
128.74 (161.00) |
25.06% | Details | |
| 7/10/2025 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
8.75 (20.10) |
129.71% | Details | |
| 7/10/2025 | Geron Corporation | GERN | New Coverage | Sell (N/A) |
1.39 (1.48) |
6.47% | Details | |
| 7/10/2025 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
6.98 (33.81) |
384.38% | Details | |
| 7/10/2025 | Altimmune | ALT | New Coverage | Sell (N/A) |
4.58 (2.89) |
-36.9% | Details | |
| 10/30/2024 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2024 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 10/3/2024 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 9/26/2024 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2024 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2024 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
44.48 (13.77) |
-69.04% | Details | |
| 9/16/2024 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | ArriVent BioPharma | AVBP | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2024 | Immunovant | IMVT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/14/2024 | CG Oncology | CGON | Upgrade | Buy (Neutral) |
28.50 (75.86) |
166.18% | Details | |
| 3/13/2024 | Immunovant | IMVT | New Coverage | Buy (N/A) |
31.50 (39.90) |
26.67% | Details | |
| 2/20/2024 | CG Oncology | CGON | New Coverage | Neutral (N/A) |
47.46 (28.50) |
-39.95% | Details | |
| 2/20/2024 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
22.07 (30.15) |
36.61% | Details |
